Krystal Biotech, Inc.
KRYS
$183.92
$1.170.64%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 290.51M | 241.52M | 166.23M | 95.95M | 50.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 290.51M | 241.52M | 166.23M | 95.95M | 50.70M |
| Cost of Revenue | 20.06M | 17.98M | 11.52M | 5.51M | 3.09M |
| Gross Profit | 270.45M | 223.54M | 154.71M | 90.44M | 47.61M |
| SG&A Expenses | 113.69M | 107.16M | 102.15M | 100.42M | 98.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 187.32M | 176.57M | 162.21M | 151.04M | 147.93M |
| Operating Income | 103.19M | 64.95M | 4.03M | -55.09M | -97.23M |
| Income Before Tax | 95.36M | 57.40M | 108.38M | 59.13M | 12.90M |
| Income Tax Expenses | 6.20M | 5.03M | 2.44M | 1.97M | 1.97M |
| Earnings from Continuing Operations | 89.16 | 52.37 | 105.94 | 57.16 | 10.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 89.16M | 52.37M | 105.94M | 57.16M | 10.93M |
| EBIT | 103.19M | 64.95M | 4.03M | -55.09M | -97.23M |
| EBITDA | 105.66M | 68.04M | 7.52M | -51.71M | -93.32M |
| EPS Basic | 3.11 | 1.83 | 3.77 | 1.98 | 0.18 |
| Normalized Basic EPS | 2.90 | 2.08 | 0.73 | -0.67 | -1.77 |
| EPS Diluted | 3.00 | 1.77 | 3.65 | 1.87 | 0.08 |
| Normalized Diluted EPS | 2.79 | 2.00 | 0.70 | -0.68 | -1.76 |
| Average Basic Shares Outstanding | 114.36M | 113.78M | 113.10M | 111.16M | 108.58M |
| Average Diluted Shares Outstanding | 118.71M | 117.65M | 116.64M | 113.66M | 110.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
